[Skip to Navigation]
Sign In

Year

Day

January 14, 2022
Original Investigation

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

Abstract Full Text
free access has active quiz
JAMA. Published online January 14, 2022. doi:10.1001/jama.2021.24939

This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living with an infected household contact.

Viewpoint

Hierarchical Payment Models—A Path for Coordinating Population- and Episode-Based Payment Models

Abstract Full Text
free access
JAMA. Published online January 14, 2022. doi:10.1001/jama.2021.23786

This Viewpoint discusses the implications from data on value-based payments, policy design regarding population- and episode-based payments, and the benefits of coordinated payment models that may contribute toward reaching the Centers for Medicare & Medicaid Services’ strategy, announced in November 2021, for achieving near-universal participation in value-based payment models by 2030.

COVID-19 Therapeutics for Nonhospitalized Patients

Abstract Full Text
free access
JAMA. Published online January 14, 2022. doi:10.1001/jama.2022.0335

This Viewpoint provides a summary of currently available therapeutics for nonhospitalized patients with COVID-19 in the setting of the Omicron variant including principles for equitable allocation.

Editorial

Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management

Abstract Full Text
free access has active quiz
JAMA. Published online January 14, 2022. doi:10.1001/jama.2021.19994
January 13, 2022
Research Letter

US Insurer Spending on Ivermectin Prescriptions for COVID-19

Abstract Full Text
free access has active quiz
JAMA. Published online January 13, 2022. doi:10.1001/jama.2021.24352

This study examines insurer coverage of ivermectin prescriptions for COVID-19 in the US.

Viewpoint

Mitigating the Long-term Health Risks of Adverse Pregnancy Outcomes

Abstract Full Text
free access
JAMA. Published online January 13, 2022. doi:10.1001/jama.2021.23870

This Viewpoint discusses the increased long-term risks for cardiovascular disease among individuals who have had adverse pregnancy outcomes and describes mitigation strategies for physicians to use over the life span of these patients.

January 12, 2022
Medical News & Perspectives

Preparing Hospitals’ Medical Oxygen Delivery Systems for a Respiratory “Twindemic”

Abstract Full Text
free access
JAMA. Published online January 12, 2022. doi:10.1001/jama.2021.23392

This Medical News feature examines the challenges that hospitals face as they prepare for a spike in severe cases of COVID-19 and other respiratory illnesses that require supplemental oxygen.

Quick Uptakes

Study: Business Booms for Unlicensed and Unproven Stem Cell Treatments

Abstract Full Text
free access
JAMA. Published online January 12, 2022. doi:10.1001/jama.2021.22793

This Medical News article examines the growing business of unlicensed and unproven stem cell treatments.

January 11, 2022
Medical News & Perspectives

COVID-19 Vaccines Have Been Available in the US for More Than a Year—What’s Been Learned and What’s Next?

Abstract Full Text
free access has multimedia has audio
JAMA. Published online January 11, 2022. doi:10.1001/jama.2022.0106

This Medical News article on COVID-19 vaccines is adapted from a JAMA interview with the CDC’s Amanda Cohn, MD.

January 10, 2022
Original Investigation

Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

Abstract Full Text
free access has active quiz
JAMA. Published online January 10, 2022. doi:10.1001/jama.2021.23641

This cohort study estimates the association of a BNT162b2 (Pfizer-BioNTech) vaccine booster dose with SARS-CoV-2 infections among health care workers in Israel previously vaccinated with a 2-dose series of BNT162b2.

Editorial

Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection

Abstract Full Text
free access
JAMA. Published online January 10, 2022. doi:10.1001/jama.2021.23726
January 7, 2022
Research Letter

False-Positive Results in Rapid Antigen Tests for SARS-CoV-2

Abstract Full Text
free access has active quiz
JAMA. Published online January 7, 2022. doi:10.1001/jama.2021.24355

This study examines the incidence of false-positive results in a sample of rapid antigen tests used to serially screen asymptomatic workers throughout Canada.

Viewpoint

Shifting to Serious Illness Communication

Abstract Full Text
free access
JAMA. Published online January 7, 2022. doi:10.1001/jama.2021.23695

This Viewpoint focuses on an emerging intervention, serious illness communication, and describes its components, presents evidence supporting the approach, and discusses areas for further research.

The Dysfunctional Health Benefits Market and Implications for US Employers and Employees

Abstract Full Text
free access
JAMA. Published online January 7, 2022. doi:10.1001/jama.2021.23258

This Viewpoint discusses addressing the problems in the health benefits market, which contribute to wage stagnation and rising economic inequality.

Diagnostic Excellence

The Rational Diagnostician and Achieving Diagnostic Excellence

Abstract Full Text
free access
JAMA. Published online January 7, 2022. doi:10.1001/jama.2021.24988

This Viewpoint outlines approaches to successfully make clinical diagnoses, including coaching medical students in critical thinking and decision-making, promoting interdisciplinary teamwork, and mitigating judgment and decision-making biases.

January 6, 2022
Viewpoint

A National Strategy for the “New Normal” of Life With COVID

Abstract Full Text
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24282

This Viewpoint discusses how US policy makers should address how the nation can move forward as the pandemic persists.

A National Strategy for COVID-19: Testing, Surveillance, and Mitigation Strategies

Abstract Full Text
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24168

This Viewpoint discusses the areas on which the US needs to improve its public health infrastructure in order to reduce COVID-19 transmission and achieve a “new normal”: testing, surveillance, masking, and ventilation.

A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics

Abstract Full Text
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24165

This Viewpoint proposes a multistep plan that US can implement to achieve a “new normal” of living, in which the combined risk of all viral respiratory illnesses, including COVID-19, does not exceed the risk during prepandemic years.

The First 2 Years of COVID-19: Lessons to Improve Preparedness for the Next Pandemic

Abstract Full Text
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24394

This Viewpoint examines the lessons that the COVID-19 pandemic can provide public health institutions and health care personnel to advance preparedness, detection, and response regarding future pandemics.

The Pandemic Preparedness Program: Reimagining Public Health

Abstract Full Text
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.23656

This Viewpoint reviews the leading objectives of the pandemic preparedness proposal, discusses the outcome of comparable past federal efforts, and emphasizes the imperative of intragovernmental coordination.

January 5, 2022
Medical News & Perspectives

Highlights From the American Heart Association’s Scientific Sessions—ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia

Abstract Full Text
free access has audio
JAMA. Published online January 5, 2022. doi:10.1001/jama.2021.21397

Timely topics discussed at the American Heart Association’s Scientific Sessions in November 2021 included using apolipoprotein B to predict the risk of future myocardial infarction.

×